Phath­om notch­es FDA ap­proval for Vo­quez­na to treat ero­sive GERD

The FDA on Thurs­day ap­proved Phath­om Phar­ma­ceu­ti­cals’ potas­si­um-com­pet­i­tive acid block­er Vo­quez­na (vono­prazan) to treat ero­sive gas­troe­sophageal re­flux dis­ease (GERD), of­fer­ing a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER